14-49625616-C-A
Variant summary
Our verdict is Likely benign. The variant received -2 ACMG points: 0P and 2B. BP4_Moderate
The NM_018139.3(DNAAF2):c.2440G>T(p.Val814Leu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000868 in 1,613,306 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 14/22 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_018139.3 missense
Scores
Clinical Significance
Conservation
Publications
- primary ciliary dyskinesia 10Inheritance: AR Classification: DEFINITIVE, STRONG, MODERATE Submitted by: Ambry Genetics, Labcorp Genetics (formerly Invitae), PanelApp Australia, ClinGen
- primary ciliary dyskinesiaInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Likely_benign. The variant received -2 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt | 
|---|---|---|---|---|---|---|---|---|
| DNAAF2 | NM_018139.3 | c.2440G>T | p.Val814Leu | missense_variant | Exon 3 of 3 | ENST00000298292.13 | NP_060609.2 | |
| DNAAF2 | NM_001083908.2 | c.2296G>T | p.Val766Leu | missense_variant | Exon 2 of 2 | NP_001077377.1 | ||
| DNAAF2 | NM_001378453.1 | c.229G>T | p.Val77Leu | missense_variant | Exon 2 of 2 | NP_001365382.1 | 
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt | 
|---|---|---|---|---|---|---|---|---|---|---|
| DNAAF2 | ENST00000298292.13 | c.2440G>T | p.Val814Leu | missense_variant | Exon 3 of 3 | 1 | NM_018139.3 | ENSP00000298292.8 | ||
| DNAAF2 | ENST00000406043.3 | c.2296G>T | p.Val766Leu | missense_variant | Exon 2 of 2 | 1 | ENSP00000384862.3 | 
Frequencies
GnomAD3 genomes  0.0000657  AC: 10AN: 152192Hom.:  0  Cov.: 32 show subpopulations 
GnomAD2 exomes  AF:  0.0000160  AC: 4AN: 250688 AF XY:  0.0000148   show subpopulations 
GnomAD4 exome  AF:  0.00000274  AC: 4AN: 1461114Hom.:  0  Cov.: 30 AF XY:  0.00000413  AC XY: 3AN XY: 726820 show subpopulations 
Age Distribution
GnomAD4 genome  0.0000657  AC: 10AN: 152192Hom.:  0  Cov.: 32 AF XY:  0.0000538  AC XY: 4AN XY: 74338 show subpopulations 
Age Distribution
ClinVar
Submissions by phenotype
Primary ciliary dyskinesia    Uncertain:2 
In summary, this variant is a rare missense change that is not predicted to affect protein function. There is no indication that it causes disease, but the available evidence is currently insufficient to prove that conclusively. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated, but these predictions have not been confirmed by published functional studies. This variant is present in population databases (rs749029870, ExAC 0.02%) but has not been reported in the literature in individuals with a DNAAF2-related disease. This sequence change replaces valine with leucine at codon 814 of the DNAAF2 protein (p.Val814Leu). The valine residue is highly conserved and there is a small physicochemical difference between valine and leucine. -
The p.V814L variant (also known as c.2440G>T), located in coding exon 3 of the DNAAF2 gene, results from a G to T substitution at nucleotide position 2440. The valine at codon 814 is replaced by leucine, an amino acid with highly similar properties. This variant was not reported in population based cohorts in the following databases: Database of Single Nucleotide Polymorphisms (dbSNP), NHLBI Exome Sequencing Project (ESP), and 1000 Genomes Project. In the ESP, this variant was not observed in 6503 samples (13006 alleles) with coverage at this position. This amino acid position is well conserved in available species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this variant remains unclear. -
Computational scores
Source: 
Splicing
 Find out detailed SpliceAI scores and Pangolin per-transcript scores at